48 results on '"Kågedal, Matts"'
Search Results
2. Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular Degeneration
3. A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis
4. Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
5. Simulation‐based evaluation of personalized dosing approaches for anti‐FGFR/KLB bispecific antibody fazpilodemab.
6. gPKPDviz: A flexible R shiny tool for pharmacokinetic/pharmacodynamic simulations using mrgsolve
7. Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
8. gPKPDviz: A flexible R shiny tool for pharmacokinetic/pharmacodynamic simulations using mrgsolve.
9. A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score
10. Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study
11. Population Pharmacokinetics of Ranibizumab Delivered via the Port Delivery System Implanted in the Eye in Patients with Neovascular Age‐Related Macular Degeneration
12. Platform model describing pharmacokinetic properties of vc-MMAE antibody–drug conjugates
13. Improved precision of exposure–response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment
14. Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers
15. Early phase drug development for treatment of chronic pain — Options for clinical trial and program design
16. A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis
17. Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
18. Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?
19. Estimation of drug receptor occupancy when non-displaceable binding differs between brain regions – extending the simplified reference tissue model
20. Pharmacokinetic–pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA)
21. A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 — Estimating occupancy in the absence of a reference region
22. Blood–Brain Barrier Penetration of Zolmitriptan—Modelling of Positron Emission Tomography Data
23. True nasopharyngeal absorption of zolmitriptan after administration via nasal spray in healthy male volunteers
24. Distribution of Zolmitriptan into the CNS in Healthy Volunteers: A Positron Emission Tomography Study
25. Modelling a Spontaneously Reported Side Effect by Use of a Markov Mixed-Effects Model
26. Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
27. Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
28. A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics
29. Analysis of Longitudinal‐Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models
30. A Study of Organic Acid Transporter-Mediated Pharmacokinetic Interaction Between NXY-059 and Cefuroxime
31. Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study
32. Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology.
33. Blood-Brain Barrier Penetration of Zolmitriptan—Modelling of Positron Emission Tomography Data
34. Time‐to‐Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine‐Citrulline‐Monomethylauristatin E Antibody–Drug Conjugates
35. Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study
36. Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study.
37. Nonlinear Mixed Effects Methods for Improved Estimation of Receptor Occupancy in PET Studies
38. Pharmacokinetic–pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA)
39. Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR
40. Autoradiographic mapping of 5-HT1B/1D binding sites in the Rhesus monkey brain using [carbonyl-11C]zolmitriptan
41. Autoradiographic Mapping of 5-HT1B/1D Binding Sites in the Rhesus Monkey Brain Using [carbonyl-11C]zolmitriptan
42. Dose-dependent binding of AZD3783 to brain 5-HT1B receptors in non-human primates and human subjects: a positron emission tomography study with [11C]AZ10419369
43. Effect of NXY-059, a novel neuroprotectant, on the pharmacokinetics of a single dose of digoxin in healthy subjects
44. Dose-dependent binding of AZD3783 to brain 5-HT receptors in non-human primates and human subjects: a positron emission tomography study with [C]AZ10419369.
45. Autoradiographic Mapping of 5-HT1B/1D Binding Sites in the Rhesus Monkey Brain Using [carbonyl-11C]zolmitriptan.
46. Extension of the simplified reference tissue model, to allow different non-specific concentrations in the brain region of interest and the reference region. Application to PET with the radioligand [11C]AZ10419369 displaced by AZD3783 at the serotonin 5HT1B receptor.
47. Blood-Brain Barrier Penetration of Zolmitriptan—Modelling of Positron Emission Tomography Data
48. Autoradiographic Mapping of 5-HT(1B/1D) Binding Sites in the Rhesus Monkey Brain Using [carbonyl-C]zolmitriptan.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.